Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1038/ejcn.2012.60. Epub 2012 Jun 6.
Affiliations
- PMID: 22669332
- DOI: 10.1038/ejcn.2012.60
Randomized Controlled Trial
Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial
C Signori et al. Eur J Clin Nutr. 2012 Aug.
Abstract
Background/objectives: The antiestrogen, Raloxifene (Ral) is an effective breast cancer chemopreventive agent. Omega-3 fatty acids (n-3FA) may inhibit mammary carcinogenesis. On the basis of their mechanisms of action, we test the hypothesis that a combination of n-3FA and Ral may be superior in reducing select biomarkers of breast cancer risk in women.
Subjects/methods: Postmenopausal women at increased risk for breast cancer (breast density ≥ 25%) were randomized to: (1) no intervention; (2) Ral 60 mg; (3) Ral 30 mg; (4) n-3FA (Lovaza) 4 g and (5) Lovaza 4 g+Ral 30 mg for 2 years. Reduction in breast density is the primary end point of the study. We report preliminary data on feasibility, compliance and changes in secondary end points related to IGF-I signaling, estrogen metabolism, oxidative stress and inflammation in the first group of 46 women who completed 1 year of the study.
Results: All interventions were well tolerated with excellent compliance (96 ± 1% overall) by pill count and also supported by the expected rise in both serum n-3FA and n-3FA/Omega-6 fatty acids (n-6FA) ratio in women randomized to groups 4 and 5 (P<0.05). Lovaza decreased serum triglycerides and increased high-density lipoprotein (HDL) cholesterol compared with control (P<0.05 for both). Ral reduced serum IGF-1 in a dose-dependent manner (P<0.05) while Lovaza did not. Lovaza had no effect on IGF-1 or IGFBP-3. None of the other biomarkers were affected by our treatment.
Conclusion: The combination of Lovaza and Ral is a feasible strategy that may be recommended in future breast cancer chemoprevention trials.
Similar articles
- Influence of Obesity on Breast Density Reduction by Omega-3 Fatty Acids: Evidence from a Randomized Clinical Trial.
Sandhu N, Schetter SE, Liao J, Hartman TJ, Richie JP, McGinley J, Thompson HJ, Prokopczyk B, DuBrock C, Signori C, Hamilton C, Calcagnotto A, Trushin N, Aliaga C, Demers LM, El-Bayoumy K, Manni A. Sandhu N, et al. Cancer Prev Res (Phila). 2016 Apr;9(4):275-82. doi: 10.1158/1940-6207.CAPR-15-0235. Epub 2015 Dec 29. Cancer Prev Res (Phila). 2016. PMID: 26714774 Clinical Trial. - Stearoyl-CoA desaturase-1, a novel target of omega-3 fatty acids for reducing breast cancer risk in obese postmenopausal women.
Manni A, Richie JP, Schetter SE, Calcagnotto A, Trushin N, Aliaga C, El-Bayoumy K. Manni A, et al. Eur J Clin Nutr. 2017 Jun;71(6):762-765. doi: 10.1038/ejcn.2016.273. Epub 2017 Feb 1. Eur J Clin Nutr. 2017. PMID: 28145413 Clinical Trial. - Omega-3 Fatty Acids Responsive Proteins and Reduction in Breast Density in Obese Postmenopausal Women.
Sun YW, Xu H, Benitez G, Chen KM, Stanley A, Stanley B, Zhu J, Thompson H, Manni A, El-Bayoumy K. Sun YW, et al. J Proteome Res. 2019 Sep 6;18(9):3461-3469. doi: 10.1021/acs.jproteome.9b00356. Epub 2019 Aug 14. J Proteome Res. 2019. PMID: 31369706 - Effects of raloxifene administration on serum levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein 3 levels: A systematic review and meta-analysis of randomized controlled trials.
Sun Y, Xiong Y, Meng YL, Santos HO, Athayde FL, de Souza IGO, Yang L. Sun Y, et al. Growth Horm IGF Res. 2021 Oct-Dec;60-61:101421. doi: 10.1016/j.ghir.2021.101421. Epub 2021 Jul 30. Growth Horm IGF Res. 2021. PMID: 34384975 - Combination of Antiestrogens and Omega-3 Fatty Acids for Breast Cancer Prevention.
Manni A, El-Bayoumy K, Skibinski CG, Thompson HJ, Santucci-Pereira J, Bidinotto LT, Russo J. Manni A, et al. Biomed Res Int. 2015;2015:638645. doi: 10.1155/2015/638645. Epub 2015 Aug 3. Biomed Res Int. 2015. PMID: 26339626 Free PMC article. Review.
Cited by
- Role of n-3 Polyunsaturated Fatty Acids and Exercise in Breast Cancer Prevention: Identifying Common Targets.
Abdelmagid SA, MacKinnon JL, Janssen SM, Ma DW. Abdelmagid SA, et al. Nutr Metab Insights. 2016 Oct 30;9:71-84. doi: 10.4137/NMI.S39043. eCollection 2016. Nutr Metab Insights. 2016. PMID: 27812288 Free PMC article. Review. - Oxidized derivative of docosahexaenoic acid preferentially inhibit cell proliferation in triple negative over luminal breast cancer cells.
Pogash TJ, El-Bayoumy K, Amin S, Gowda K, de Cicco RL, Barton M, Su Y, Russo IH, Himmelberger JA, Slifker M, Manni A, Russo J. Pogash TJ, et al. In Vitro Cell Dev Biol Anim. 2015 Feb;51(2):121-7. doi: 10.1007/s11626-014-9822-6. Epub 2014 Nov 21. In Vitro Cell Dev Biol Anim. 2015. PMID: 25413005 Free PMC article. - Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.
Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, Horne R, Wardle J, Cuzick J. Smith SG, et al. Ann Oncol. 2016 Apr;27(4):575-90. doi: 10.1093/annonc/mdv590. Epub 2015 Dec 8. Ann Oncol. 2016. PMID: 26646754 Free PMC article. - Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo.
Sun D, Jones NR, Manni A, Lazarus P. Sun D, et al. Cancer Prev Res (Phila). 2013 Jul;6(7):719-30. doi: 10.1158/1940-6207.CAPR-12-0448. Epub 2013 May 16. Cancer Prev Res (Phila). 2013. PMID: 23682072 Free PMC article. - Emerging targets in lipid-based therapy.
Tucker SC, Honn KV. Tucker SC, et al. Biochem Pharmacol. 2013 Mar 1;85(5):673-688. doi: 10.1016/j.bcp.2012.11.028. Epub 2012 Dec 20. Biochem Pharmacol. 2013. PMID: 23261527 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous